Eiger BioPharmaceuticals Inc

NASDAQ EIGRQ

Data sourced from iex and EODHD
Download Data

Eiger BioPharmaceuticals Inc Inventory Turnover Ratio 1 year YoY Change (%) for the year ending December 31, 2023: -97.60%

Eiger BioPharmaceuticals Inc Inventory Turnover Ratio 1 year YoY Change (%) is -97.60% for the year ending December 31, 2023, a -177.62% change year over year. The inventory turnover ratio measures the efficiency of a company's inventory management by assessing how quickly it sells and replaces its inventory. It is calculated by dividing the cost of revenue by the average inventory value. This ratio indicates the number of times the company's inventory is sold and replaced within a specific period. A higher turnover ratio suggests efficient inventory management, while a lower ratio may indicate slow sales or excess inventory. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Eiger BioPharmaceuticals Inc Inventory Turnover Ratio for the year ending December 31, 2022 was 0.64, a 125.75% change year over year.
  • Eiger BioPharmaceuticals Inc Inventory Turnover Ratio for the year ending December 31, 2021 was 0.29, a 0.00% change year over year.
  • Eiger BioPharmaceuticals Inc Inventory Turnover Ratio for the year ending December 31, 2020 was 0.00.
NASDAQ: EIGRQ

Eiger BioPharmaceuticals Inc

CEO -
IPO Date Jan. 30, 2014
Location United States
Headquarters 2155 Park Boulevard, Palo Alto, CA, United States, 94306
Employees 25
Sector Healthcare
Industry Biotechnology
Description

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

StockViz Staff

September 19, 2024

Any question? Send us an email